Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial

Muthiah Vaduganathan, Christopher P. Cannon, Byron Cryer, Yuyin Liu, Wen-Hua Hsieh, Gheorghe Doros, Marc Cohen, Ángel Lanas, Thomas J. Schnitzer, Thomas Shook, Pablo Lapuerta, Mark A. Goldsmith, Loren Laine, Deepak L. BhattThe American Journal of Medicine 2016 · DOI

TL;DR

This study investigated whether proton-pump inhibitors (PPIs) like omeprazole could reduce gastrointestinal (GI) bleeding in high-risk cardiovascular patients also taking dual antiplatelet therapy (DAPT), without increasing their risk of major adverse cardiovascular events. The findings suggest that PPIs are effective in reducing GI bleeding in these patients, offering a safe gastroprotective strategy.

What Problem Does This Paper Address?

Patients undergoing procedures like percutaneous coronary intervention (PCI) or those who have experienced an acute coronary syndrome (ACS) are often prescribed dual antiplatelet therapy (DAPT) to prevent blood clots. However, DAPT significantly increases the risk of gastrointestinal (GI) bleeding. Proton-pump inhibitors (PPIs) are commonly used to mitigate this GI risk, but there's been ongoing debate about their efficacy and safety, particularly concerning potential interactions with antiplatelet drugs like clopidogrel and whether they might increase cardiovascular events. This paper specifically addresses the question of whether PPIs are safe and effective in high-risk cardiovascular subsets of patients who are already on DAPT, aiming to clarify their role in this vulnerable population.

Methods

This paper presents post hoc analyses of the COGENT trial, which was a randomized, double-blind, placebo-controlled trial. The original trial evaluated the efficacy and safety of omeprazole combined with clopidogrel versus clopidogrel alone in patients with coronary artery disease on DAPT. For these specific analyses, the researchers focused on two high-risk subgroups:

  1. Patients who underwent PCI within 14 days of randomization.
  2. Patients who presented with ACS.

They used unadjusted Cox proportional hazards models to estimate the effect sizes of PPI treatment on GI and cardiovascular outcomes through the final follow-up period.

Datasets

The data for this study comes from the COGENT (Clopidogrel and the Optimization of Gastrointestinal Events Trial) trial. This was a prospective, randomized, placebo-controlled trial. No new datasets were introduced.

Key Insights and Ideas

  • PPIs are effective gastroprotectants in high-risk cardiovascular patients: The study confirms that PPIs significantly reduce the risk of GI bleeding in patients on DAPT after PCI or ACS. This is crucial because GI bleeding in these patients is associated with poor outcomes.
  • No increased cardiovascular risk: A key finding is that omeprazole did not increase the risk of major adverse cardiovascular events in these high-risk subgroups. This addresses a significant concern about potential drug interactions between PPIs and antiplatelet agents.
  • Broad applicability of PPIs: The benefits of PPIs in reducing GI risk were observed regardless of the specific indication for DAPT (PCI or ACS), suggesting a generalizable benefit for these high-risk populations.
  • Addressing a clinical dilemma: The study provides evidence to support the common practice of continuing PPI therapy post-discharge for patients at high risk of GI bleeding, even when they are on DAPT.

Key Results

  • In patients undergoing PCI, omeprazole significantly reduced composite GI events at 180 days (1.2% vs. 2.7%; HR 0.43, 95% CI 0.22-0.85; p=0.02).
  • This reduction in GI events was achieved without an increase in composite cardiovascular events (5.4% vs. 6.3%; HR 1.00, 95% CI 0.67-1.50; p=1.00).
  • Similarly, in patients presenting with ACS, omeprazole lowered the risk of the primary GI endpoint at 180 days (1.1% vs. 2.7%; HR 0.37, 95% CI 0.13-1.01; p=0.05).
  • Again, this was without a significant excess in cardiovascular events (5.6% vs. 4.5%; HR 1.40, 95% CI 0.77-2.53; p=0.27).

Limitations and Future Work

The authors acknowledge several limitations:

  • Premature termination of the trial: The COGENT trial was stopped early due to funding issues, meaning it may have been underpowered to detect smaller differences, particularly in cardiovascular events.
  • Lack of adjustment for multiple comparisons: The analyses did not account for multiple comparisons, which could potentially inflate the risk of Type I errors.
  • Combination formulation: The trial used a combination formulation of clopidogrel and omeprazole that is not commercially available, although the authors suggest this is unlikely to affect the results.
  • Subgroup analysis: These are post hoc analyses, which are inherently exploratory and should be interpreted with caution.

Future studies are needed to clarify optimal gastroprotective strategies, especially for higher-intensity and longer durations of DAPT. The COMPASS trial is mentioned as a future study that will shed further light on optimal gastroprotective strategies in high-risk CAD patients requiring more potent antithrombotic combinations for longer durations.

Summary updated

BibTeX
@article{vaduganathan2016efficacy,
  author = {Muthiah Vaduganathan and Christopher P. Cannon and Byron Cryer and Yuyin Liu and Wen-Hua Hsieh and Gheorghe Doros and Marc Cohen and Ángel Lanas and Thomas J. Schnitzer and Thomas Shook and Pablo Lapuerta and Mark A. Goldsmith and Loren Laine and Deepak L. Bhatt},
  title = {{Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial}},
  journal = {The American Journal of Medicine},
  year = {2016},
  doi = {10.1016/j.amjmed.2016.03.042},
}
Figure